Tim Lu’s quest to break new cell therapy ground with gene circuits gets Bayer’s backing in a big new financing round
When Tim Lu spun himself out of MIT to devote some serious attention to his biotech startup Senti Biosciences more than 3 years ago, it was clear from the beginning that he was attempting to break some completely new ground in drug development. Mixing an academic background that included a Harvard Med education with a computer sciences background at MIT, he had been laboring on a new approach to program drugs to operate in a better way — using his synthetic gene circuits to command more selective target engagement.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,600+ biopharma pros reading Endpoints daily — and it's free.